13 January 2022 - Second approved indication after invasive mucormycosis in December 2021.
Basilea Pharmaceutica announced today that its license partner, Pfizer has received a drug approval license from the National Medical Products Administration in China, for the oral formulation of its antifungal Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis.